TPG Invests $75 Million into Precision For Medicine – PharmaLive
PharmaLive covers TPG’s significant investment in Precision Medicine Group
TPG bets $75M on Pharma Service Provider Precision for Medicine – FierceCRO
TPG partner Kevin Hobart discusses the equity firm’s investment in Precision Medicine Group with Damian Garde for Fierce Biotech,
TPG Growth Invests $75 Million in Precision for Medicine
Leader in Healthcare Investing Acquires Stake in Growing Pharmaceutical Services Company
Fort Worth, Texas, San Francisco and Bethesda, MD — December 22, 2015 — TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.
Congress Considers Regulation of Lab-Developed Tests – Roll Call
Precision for Medicine’s Karen M. Becker, PhD, Managing Director, Translational and Regulatory Science, is quoted in an article regarding the upcoming Food and Drug Administration’s guidance on how it plans to oversee lab-developed tests used to diagnose conditions. Read the full article below:
By Andrew Siddons
Biosimilars: What’s in a Name? – Pharmaceutical Commerce Magazine
Precision for Value’s Jeremy Schafer is quoted in an article that discusses the naming of biosimilars. He concludes that the payer community will find a way to track biosimilar sourcing, usage and reimbursement regardless of naming conventions or HCPCS codes.
Q&A: Regulatory Expert Karen Becker Provides Context for Theranos, FDA Interactions – GenomeWeb
Karen M. Becker, PhD, Managing Director, Translational and Regulatory Sciences at Precision for Medicine, provides expertise for the diagnostics industry in navigating the complexities of the Food and Drug Administration.
Precision for Medicine acquires Redwood Outcomes, a Canadian HEOR firm – Pharmaceutical Commerce Magazine
Precision for Value, a unit of New York-based Precision for Medicine, is adding Redwood Outcomes, based in Vancouver, BC to its stable.
Commentary: Biosimilars – Why Deep Discounts May Become the Dominant Paradigm
Precision for Value’s Jeremy Schafer, Michael Tapella, and Thanos Kantarelis conclude that discounts in the biosimilar market may be significantly deeper than originally expected.
Precision for Value Acquires Redwood Outcomes – NJBIZ
Dan Renick is quoted in NJBIZ on Precision’s Redwood Outcomes HEOR acquisition.
Precision for Value Buys Health Economics Firm – Medical Marketing & Media
Precision’s acquisition of Redwood Outcomes is noted in Medical Marketing & Media.